Rajasekhar Ramakrishnan
YOU?
Author Swipe
View article: Bioelectrocatalytic Carbon dioxide (CO2) Reduction by Tungsten-dependent Formate Dehydrogenases
Bioelectrocatalytic Carbon dioxide (CO2) Reduction by Tungsten-dependent Formate Dehydrogenases Open
View article: The effectiveness of synchronous online clinics and conventional clinics among medical students: Assessing the influence of e-learning
The effectiveness of synchronous online clinics and conventional clinics among medical students: Assessing the influence of e-learning Open
The COVID-19 pandemic presented challenges that led to the development of on-line learning, emphasizing how important it is for students to have access to quality education. This study was conducted to compare the efficacy of synchronous o…
View article: Association of free-living diet composition with plasma lipoprotein(a) levels in healthy adults
Association of free-living diet composition with plasma lipoprotein(a) levels in healthy adults Open
Background Lipoprotein (a) [Lp(a)] is an apoB100-containing lipoprotein with high levels being positively associated with atherosclerotic cardiovascular disease. Lp(a) levels are genetically determined. However, previous studies report a n…
View article: TM6SF2 Determines Both the Degree of Lipidation and the Number of VLDL Particles Secreted by the Liver
TM6SF2 Determines Both the Degree of Lipidation and the Number of VLDL Particles Secreted by the Liver Open
In 2014, exome-wide studies identified a glutamine176lysine (p.E167K) substitution in a protein of unknown function named transmembrane 6 superfamily member 2 (TM6SF2). The p.E167K variant was associated with increased hepatic fat content …
View article: Effects of Administration of Recombinant Human Lecithin-Cholesterol Acyltransferase on Lipoprotein Metabolism in Humans
Effects of Administration of Recombinant Human Lecithin-Cholesterol Acyltransferase on Lipoprotein Metabolism in Humans Open
Lecithin cholesterol acyl transferase (LCAT) catalyzes the conversion of unesterified, or free cholesterol (FC), to cholesteryl ester (CE), which moves from the surface of HDL into the neutral lipid core. As this iterative process continue…
View article: Association of Free-Living Diet Composition and Plasma Lipoprotein(a) Levels in Healthy Adults
Association of Free-Living Diet Composition and Plasma Lipoprotein(a) Levels in Healthy Adults Open
Background Lipoprotein (a) [Lp(a)] is an apoB100-containing lipoprotein with high levels positively associated with atherosclerotic cardiovascular disease (ASCVD). Lp(a) levels are largely genetically determined. Currently, the only approv…
View article: Relationship of apolipoprotein(a) isoform size with clearance and production of lipoprotein(a) in a diverse cohort
Relationship of apolipoprotein(a) isoform size with clearance and production of lipoprotein(a) in a diverse cohort Open
Lipoprotein(a) [Lp(a)] has two main proteins, apoB100 and apo(a). High levels of Lp(a) confer an increased risk for atherosclerotic cardiovascular disease. Most people have two circulating isoforms of apo(a) differing in their molecular ma…
View article: Medical weight management protects against weight gain during the COVID‐19 pandemic
Medical weight management protects against weight gain during the COVID‐19 pandemic Open
Background American adults have gained weight during the COVID‐19 pandemic. Little is known about how patients who are medically managed for overweight and obesity, including patients who are prescribed antiobesity pharmacotherapy, have fa…
View article: Personalized Reminders for Immunization Using Short Messaging Systems to Improve Human Papillomavirus Vaccination Series Completion: Parallel-Group Randomized Trial
Personalized Reminders for Immunization Using Short Messaging Systems to Improve Human Papillomavirus Vaccination Series Completion: Parallel-Group Randomized Trial Open
Background Completion rates among adolescents who initiate the human papillomavirus (HPV) vaccine 3-dose series are low. SMS text message vaccine reminders are effective, but less is known about the best types for HPV series completion or …
View article: Effect of Electronic Health Record Reminders for Routine Immunizations and Immunizations Needed for Chronic Medical Conditions
Effect of Electronic Health Record Reminders for Routine Immunizations and Immunizations Needed for Chronic Medical Conditions Open
Background Immunization reminders in electronic health records (EHR) provide clinical decision support (CDS) that can reduce missed immunization opportunities. Little is known about using CDS rules from a regional immunization information …
View article: Weight‐loss response to naltrexone/bupropion is modulated by the <scp>Taq1A</scp> genetic variant near <scp> <i>DRD2</i> </scp> ( <scp>rs1800497</scp> ): A pilot study
Weight‐loss response to naltrexone/bupropion is modulated by the <span>Taq1A</span> genetic variant near <span> <i>DRD2</i> </span> ( <span>rs1800497</span> ): A pilot study Open
Naltrexone/bupropion (NB) is a US Food and Drug Administration‐approved antiobesity medication. Clinical trials have shown variable weight loss, with responders and non‐responders. NB is believed to act on central dopaminergic pathways to …
View article: Acute injection of a DHA triglyceride emulsion after hypoxic-ischemic brain injury in mice increases both DHA and EPA levels in blood and brain✰
Acute injection of a DHA triglyceride emulsion after hypoxic-ischemic brain injury in mice increases both DHA and EPA levels in blood and brain✰ Open
View article: Role of Growth factors (HB-EGF, VEGF-A) and Immunotolerance Mediators (TNF-αIFN-γ,PD-L1 and IL-10) in Acute and Chronic Otitis Media
Role of Growth factors (HB-EGF, VEGF-A) and Immunotolerance Mediators (TNF-αIFN-γ,PD-L1 and IL-10) in Acute and Chronic Otitis Media Open
Objectives There is an increasing evidence of immune mediated mechanism in the etiopathogenesis of Otitis Media – ‘middle ear inflammation’. The aim of the present study was to determine the expression of important circulatoryregulators of…
View article: The Type and Amount of Dietary Fat Affect Plasma Factor VIIc, Fibrinogen, and PAI-1 in Healthy Individuals and Individuals at High Cardiovascular Disease Risk: 2 Randomized Controlled Trials
The Type and Amount of Dietary Fat Affect Plasma Factor VIIc, Fibrinogen, and PAI-1 in Healthy Individuals and Individuals at High Cardiovascular Disease Risk: 2 Randomized Controlled Trials Open
View article: Cholesterol Stabilizes TAZ in Hepatocytes to Promote Experimental Non-alcoholic Steatohepatitis
Cholesterol Stabilizes TAZ in Hepatocytes to Promote Experimental Non-alcoholic Steatohepatitis Open
View article: Vitamin E absorption and kinetics in healthy women, as modulated by food and by fat, studied using 2 deuterium-labeled α-tocopherols in a 3-phase crossover design
Vitamin E absorption and kinetics in healthy women, as modulated by food and by fat, studied using 2 deuterium-labeled α-tocopherols in a 3-phase crossover design Open
View article: Effects of <i>APOC3</i> Heterozygous Deficiency on Plasma Lipid and Lipoprotein Metabolism
Effects of <i>APOC3</i> Heterozygous Deficiency on Plasma Lipid and Lipoprotein Metabolism Open
Objective— Apo (apolipoprotein) CIII inhibits lipoprotein lipase (LpL)-mediated lipolysis of VLDL (very-low-density lipoprotein) triglyceride (TG) and decreases hepatic uptake of VLDL remnants. The discovery that 5% of Lancaster Old Order …
View article: An ATF6-tPA pathway in hepatocytes contributes to systemic fibrinolysis and is repressed by DACH1
An ATF6-tPA pathway in hepatocytes contributes to systemic fibrinolysis and is repressed by DACH1 Open
Tissue-type plasminogen activator (tPA) is a major mediator of fibrinolysis and, thereby, prevents excessive coagulation without compromising hemostasis. Studies on tPA regulation have focused on its acute local release by vascular cells i…
View article: Effects of mipomersen, an apolipoprotein B100 antisense, on lipoprotein (a) metabolism in healthy subjects
Effects of mipomersen, an apolipoprotein B100 antisense, on lipoprotein (a) metabolism in healthy subjects Open
Elevated lipoprotein (a) [Lp(a)] levels increase the risk for CVD. Novel treatments that decrease LDL cholesterol (LDL-C) have also shown promise for reducing Lp(a) levels. Mipomersen, an antisense oligonucleotide that inhibits apoB synthe…
View article: MerTK signaling in macrophages promotes the synthesis of inflammation resolution mediators by suppressing CaMKII activity
MerTK signaling in macrophages promotes the synthesis of inflammation resolution mediators by suppressing CaMKII activity Open
Signaling by the receptor MerTK in macrophages promotes ERK activation and the resolution of inflammation.
View article: Metformin and AMP Kinase Activation Increase Expression of the Sterol Transporters ABCG5/8 (ATP-Binding Cassette Transporter G5/G8) With Potential Antiatherogenic Consequences
Metformin and AMP Kinase Activation Increase Expression of the Sterol Transporters ABCG5/8 (ATP-Binding Cassette Transporter G5/G8) With Potential Antiatherogenic Consequences Open
Objective— The mechanisms underlying the cardiovascular benefit of the anti-diabetic drug metformin are poorly understood. Recent studies have suggested metformin may upregulate macrophage reverse cholesterol transport. The final steps of …
View article: FoxO transcription factors are required for hepatic HDL cholesterol clearance
FoxO transcription factors are required for hepatic HDL cholesterol clearance Open
Insulin resistance and type 2 diabetes are associated with low levels of high-density lipoprotein cholesterol (HDL-C). The insulin-repressible FoxO transcription factors are potential mediators of the effect of insulin on HDL-C. FoxOs medi…
View article: CETP (Cholesteryl Ester Transfer Protein) Inhibition With Anacetrapib Decreases Production of Lipoprotein(a) in Mildly Hypercholesterolemic Subjects
CETP (Cholesteryl Ester Transfer Protein) Inhibition With Anacetrapib Decreases Production of Lipoprotein(a) in Mildly Hypercholesterolemic Subjects Open
Objective— Lp(a) [lipoprotein (a)] is composed of apoB (apolipoprotein B) and apo(a) [apolipoprotein (a)] and is an independent risk factor for cardiovascular disease and aortic stenosis. In clinical trials, anacetrapib, a CETP (cholestery…
View article: Effects of CETP inhibition with anacetrapib on metabolism of VLDL-TG and plasma apolipoproteins C-II, C-III, and E
Effects of CETP inhibition with anacetrapib on metabolism of VLDL-TG and plasma apolipoproteins C-II, C-III, and E Open
View article: Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans
Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans Open
Background: Alirocumab, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9), lowers plasma low-density lipoprotein (LDL) cholesterol and apolipoprotein B100 (apoB). Although studies in mice and cells have identif…
View article: Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects
Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects Open
the JCI that multiple microscopy images in Figure 2B were previously published and were used to represent different samples in another publication by the corresponding author's group (1).The authors have stated that experimental data produ…
View article: Cholesteryl Ester Transfer Protein Inhibition With Anacetrapib Decreases Fractional Clearance Rates of High-Density Lipoprotein Apolipoprotein A-I and Plasma Cholesteryl Ester Transfer Protein
Cholesteryl Ester Transfer Protein Inhibition With Anacetrapib Decreases Fractional Clearance Rates of High-Density Lipoprotein Apolipoprotein A-I and Plasma Cholesteryl Ester Transfer Protein Open
Objective— Anacetrapib (ANA), an inhibitor of cholesteryl ester transfer protein (CETP) activity, increases plasma concentrations of high-density lipoprotein cholesterol (HDL-C), apolipoprotein A-I (apoA)-I, apoA-II, and CETP. The mechanis…
View article: Complex effects of inhibiting hepatic apolipoprotein B100 synthesis in humans
Complex effects of inhibiting hepatic apolipoprotein B100 synthesis in humans Open
Targeting apoB synthesis with mipomersen (KYNAMRO) can be effective for lowering plasma levels of apoB lipoproteins without reducing the secretion of VLDL.
View article: Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects
Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects Open
Merck & Co. Inc., Kenilworth, New Jersey, USA. Additional support for instrumentation was obtained from the National Center for Advancing Translational Sciences (UL1TR000003 and UL1TR000040).